Pharmacological treatment of schizophrenia

References

• ADA-AP (2004). American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obesity Research, 12, 362–368.
   PubMedGoogle Scholar
• Adams, C.E., Fenton, M.K., Quraishi, S. & David, A.S. (2001). Systematic meta-review of depot antipsychotics drugs for people with schizophrenia. British Journal of Psychiatry, 179, 290–299.
   PubMed Web of Science ®Google Scholar
• Alvir, J.M.J., Lieberman, J.A., Safferman, A.Z., Schwimmer, J.L. & Schaaf, J.A. (1993). Clozapine-induced agranulocytosis: Incidence and risk factor in the United States. New England Journal of Medicine, 329, 162–167.
   PubMed Web of Science ®Google Scholar
• Andreasen, N.C., Carpenter, W.T., Kane, J.M., Lasser, R.A., Marder, S.R. & Weinberger, D.R. (2005). Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry, 162, 441–449.
   PubMed Web of Science ®Google Scholar
• APA (2004). Practice Guideline for the Treatment of Patients with Schizophrenia (2nd ed.). Washington, DC: American Psychiatric Press.
   Google Scholar
• Bowie, C.R., Reichenberg, A., Patterson, T.L., Heaton, R.K. & Harvey, P.D. (2006). Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognitive, functional capacity and symptoms. American Journal of Psychiatry, 163, 418–425.
   PubMed Web of Science ®Google Scholar
• Brown, S., Kim, M., Mitchell, C. & Inskip, H. (2010). Twenty-five year mortality of a community cohort with schizophrenia. British Journal of Psychiatry, 196, 116–121.
   PubMed Web of Science ®Google Scholar
• Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Keller, W. (2010). Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36, 71–93.
   PubMed Web of Science ®Google Scholar
• Capasso, R.M., Lineberry, T.W., Bostwick, J.M., Decker, P.A. & StSauver, J. (2008). Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950–2005. Schizophrenia Research, 98, 287–294.
   PubMed Web of Science ®Google Scholar
• Claghorn, J., Honigfeld, G., Abuzzahab, F.S., WangR, Steinbook, R., Tuason, V. & Klerman, G. (1987). The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology, 7, 377–384.
   PubMed Web of Science ®Google Scholar
• Correll, C.U., Frederickson, A.M., Kane, J.M. & Manu, P. (2006). Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. Journal of Clinical Psychiatry, 67, 575–83.
   PubMed Web of Science ®Google Scholar
• Crisholm, D., Gureje, O., Saldivia, S., Calderon, M.V., Wickremasinghe, R., Mendis, N., Saxena, S. (2008). Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bulletin of the World Health Organization, 86, 542–551.
   PubMed Web of Science ®Google Scholar
• Delay J, Deniker P, Harl JM. (1952). [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. Ann Med Psychol (Paris), 110, 112–7.
   PubMedGoogle Scholar
• Edwards, N.C., Locklear, J.C., Rupnow, M.F.T. & Diamond, R.J. (2005). Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics, 23, S75–89.
   PubMed Web of Science ®Google Scholar
• Elkis, H., Gama, C., Suplicy, H., TambasciaI, M., Bressan, R.A., Lyra, R., ...Minicucci, W. (2008). Brazilian consensus on second-generation antipsychotics and metabolic disorders. Revista Brasileira de Psiquiatria, 30, 77–85.
   PubMed Web of Science ®Google Scholar
• Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F. & Möller, H.J. (2005). WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry, 6, 132–191.
   PubMed Web of Science ®Google Scholar
• Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F. & Möller, H.J. (2006). WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry, 7, 5–40.
   PubMed Web of Science ®Google Scholar
• Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ, 321, 1371–1376.
   PubMed Web of Science ®Google Scholar
• Gentile, S. (2010). Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophrenia Bulletin, 36, 518–544.
   PubMed Web of Science ®Google Scholar
• Grundy, S.M., Brewer, H.B., Cleeman, J.I., Smith, S.C. & Lenfant, C. (2004). Definition of metabolic syndrome: Report of the National, Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109, 433–438.
   PubMed Web of Science ®Google Scholar
• Hennekens, C.H., Hennekens, A.R., Hollar, D. & Casey, D.E. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150, 1115–1121.
   PubMed Web of Science ®Google Scholar
• Hert, M., Dekker, J.M., Wood, D., Kahl, K.G., Holt, R.I.G. & Möller, H.J. (2009). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry, 24, 412–424.
   PubMed Web of Science ®Google Scholar
• Hippius, H. (1999). A historical perspective of clozapine. Journal of Clinical Psychiatry, 60S12, S22–23.
   Google Scholar
• Hofer, A., Kemmler, G., Eder, U., Edlinger, M., Hummer, M. & Feischhacker, W.W. (2004). Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication and side effects. Journal of Clinical Psychiatry, 65, 932–939.
   PubMed Web of Science ®Google Scholar
• Huskamp, H.A. (2006). Prices, profits, and innovation: Examining criticisms of new psychotropic drugs’ value. Health Affairs, 25, 635–646.
   Web of Science ®Google Scholar
• International Psychopharmacology Algorithm Project (IPAP). (2006). Schizophrenia Algorithm, Available at www.ipap.org
   Google Scholar
• Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P.M., ...Gschwandtner, U. (2008). Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: An open randomized clinical trial. Lancet, 371, 1085–1096.
   PubMed Web of Science ®Google Scholar
• Kane, J.M. (2008). An evidence-based strategy for remission in schizophrenia. Journal of Clinical Psychiatry, 69, 25–30.
   PubMed Web of Science ®Google Scholar
• Kane, J., Honigfeld, G., Singer, J. & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.
   PubMed Web of Science ®Google Scholar
• Kapur, S. & Seeman, P. (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry, 158, 360–369.
   PubMed Web of Science ®Google Scholar
• Kapur, S., Zipursky, R., Jones, C., Remington, G. & Houle, S. (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157, 514–520.
   PubMed Web of Science ®Google Scholar
• Klaussen, K.P., Parving, H.H., Schaling, H. & Jensen, J.S. (2007). The association between metabolic syndrome, micoralbuminuria and impaired renal function in the general population: Impact on cardiovascular disease and mortality. Journal of Internal Medicine, 262, 470–478.
   PubMed Web of Science ®Google Scholar
• Lambert, M., Conus, P., Eide, P., Mass, R., Karow, A., Moritz, S., ...Naber, D. (2004). Impact of present and past antipsychotic side effects on attitute toward typical antipsychotic treatment and adherece. European Psychiatry, 19, 415–422.
   PubMed Web of Science ®Google Scholar
• Leucht, S., Arbter, D., Engel, R.R., Kissling, W. & Davis, J.M. (2009a). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry, 14, 429–447.
   Google Scholar
• Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C. & Davis, J.M. (2009b). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373, 31–41.
   PubMed Web of Science ®Google Scholar
• Leucht, S. & Heres, S. (2006). Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. Journal of Clinical Psychiatry, 67S5, S3–8.
   Google Scholar
• Leucht, S., Pitschel-Wals, G., Abraham, D. & Kissling, W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperido, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51–68.
   Google Scholar
• Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, S., Rosenheck, R.A., Perkins, D.O., ..Hsiao, J.K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.
   PubMed Web of Science ®Google Scholar
• Lincoln, T.M., Wilhelm, K. & Nestoriuc, Y. (2007). Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: A meta-analysis. Schizophrenia Research, 96, 232–245.
   PubMed Web of Science ®Google Scholar
• Mari, J.J., Razzouk, D., Thara, R., Eaton, J. & Thornicroft, G. (2009). Packages of care for schizophrenia in low- and middle-income countries. PLoS Medicine, 6, 10, e1000165. doi:10.1371/journal.pmed.1000165.
   Web of Science ®Google Scholar
• Masand, P.S., Roca, M., Turner, M.S. & Kane, J.M. (2009). Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review. Primary Care Companion to the Journal of Clinical Psychiatry, 11, 147–154.
   PubMedGoogle Scholar
• Matza, C.S., Buchanan, R., Purdon, S., Brewster-Jordan, J., Zhao, Y. & Revicki, D.A. (2006). Measuring changes in functional status among patients with schizophrenia: The link with cognitive impairment. Schizophrenia Bulletin, 32, 666–678.
   PubMed Web of Science ®Google Scholar
• McEvoy, J.P., Lieberman, J.A., Stroup, T.S., Davis, S.M., Meltzer, H.Y., Rosenheck, R.A., ...Hsiao, J.K. (2006). Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry, 163, 600–610.
   PubMed Web of Science ®Google Scholar
• McEvoy, J.P., Meyer, J.M. & Goff, D.C. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19–32.
   PubMed Web of Science ®Google Scholar
• Mitchell, A.J. & Lord, O. (2010). Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. Journal of Psychopharmacology, 24S4, 69–80.
   Google Scholar
• Munro, J., O'Sullivan, D., Andrews, C., Arana, A., Mortimer, A. & Kerwin, R. (1999). Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. British Journal of Psychiatry, 175, 576–570.
   PubMed Web of Science ®Google Scholar
• Nasr, T. & Kausar, R. (2009). Psychoeducation and the family burden in schizophrenia: A randomized controlled trial. Annals of General Psychiatry, 8, 17. doi:10.1186/1744 -859X-8-1.
   PubMedGoogle Scholar
• NCCMH (2010) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. Leicester and London: British Psychological Society and the Royal College of Psychiatrists.
   Google Scholar
• Newcomer, J.W. (2004). Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. Journal of Clinical Psychiatry, 65S18, 34–46.
   Google Scholar
• Newcomer, J.W. (2007). Antipsychotic medications: Metabolic and cardiovascular risk. Journal of Clinical Psychiatry, 68, 8–13.
   PubMed Web of Science ®Google Scholar
• NICE (2002). Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: National Institute for Clinical Excellence.
   Google Scholar
• Patterson, T.L. & Leeuwenkamp, O.R. (2008). Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophrenia Research, 100, 108–119.
   PubMed Web of Science ®Google Scholar
• Perkins, D.O. (2002). Predictor of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63, 1121–1128.
   PubMed Web of Science ®Google Scholar
• RANZCP CPG Team (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39, 1–30.
   PubMed Web of Science ®Google Scholar
• Robinson, D., Woerner, M.G., Alvir, J.M.J., Bilder, R., Goldman, R., Geisle, S., ...Lieberman, J.A. (1999). Predictors of relapse following response from a first-episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241–247.
   PubMed Web of Science ®Google Scholar
• Rocha, D.M.L.V., Neto, J.B.B., Elkis, H. & Bressan, R.A. (2010). Terapêutica com clozapina [Treatment with clozapine]. In R.A. Bressan & H. Elkis (Eds), Esquizofrenia refratária [Refractory schizophrenia] (2nd ed.). São Paulo, Segmento Farma.
   Google Scholar
• Rosenbloom, M. (2002). Chlorpromazine and psychopharmaco-logic revolution. Journal of the American Medical Association, 287, 1860–1861.
   Google Scholar
• Rummel-Kluge, C., Komossa, K., Schwartz, S., Hunger, H., Schmid, F., Lobos, C.A., ...Leucht, S. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 123, 225–233.
   PubMed Web of Science ®Google Scholar
• Saha, S., Chant, D. & McGrath, J. (2007). A systematic review of mortality in Schizophrenia. Archives of General Psychiatry, 64, 1123–1131.
   PubMed Web of Science ®Google Scholar
• Shirakawa, I. (2007). Esquizofrenia: adesão ao tratamento [Schizophrenia: compliance with treatment]. São Paulo: Casa Editorial Lemos.
   Google Scholar
• Stahl, S.M. (2011). Stahl's Essential Psychopharmacology: The Prescriber's Guide (4th ed.). New York: Cambridge University Press.
   Google Scholar
• Üçok, A., Incesu, C., Aker, T. & Erkoç, S. (2007). Sexual dysfunction in patients with schizophrenia on antipsychotic medication. European Psychiatry, 22, 328–333.
   PubMed Web of Science ®Google Scholar
• Velligan, D.I., Diamond, P.M., Mintz, J., Maples, N., Li, X., Zeber J., ...Miller, A.L. (2008). The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophrenia Bulletin, 34, 483–493.
   PubMed Web of Science ®Google Scholar
• Weiden, P.J. (2007). EPS profiles: The atypical antipsychotics are not the same. Journal of Psychiatric Practice, 13, 13–24.
   PubMedGoogle Scholar
• Weiden, P.J. & Buckley, P.F. (2007). Reducing the burden of side effects during long-term antipsychotic therapy: The role of ‘switching’ medications. Journal of Clinical Psychiatry, 68, 14–23.
   Web of Science ®Google Scholar
• Weiden, P.J. & Zygmunt, A. (1997). The road back: Working with severely mentally ill. Medication noncompliance in schizophrenia. Part. 1: Assessment. Journal of Practical Psychiatry and Behavioral Health, 3, 106–110.
   Google Scholar
• Young, C.R., Bowers, M.B. Jr & Manure, C.M. (1998). Management of the adverse effects of clozapine. Schizophrenia Bulletin, 24, 381–390.
   PubMed Web of Science ®Google Scholar